immupharma.co.uk Report : Visit Site

Technical data of the immupharma.co.uk

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host immupharma.co.uk. Currently, hosted in Germany and its service provider is 1&1 Internet AG .

the related websites

iii.co.uk shareprice.co.uk lse.co.uk hl.co.uk www-uk.computershare.com shorttracker.co.uk aimlisting.co.uk internationalfundforireland.com 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

about us about us corporate strategy our vision and values research & development operations business development awards and grants announcements our team management team scientific team scientific advisory board portfolio our portfolio lupuzor™ auto-immune diseases oncology & ophthalmology metabolism and diabetes investors investor relations aim rule 26 information regulatory news market commentary share price broker research corporate governance board of directors annual reports presentations interviews professional advisers email alerts media events and conferences media room interviews scientific publications contact us lupuzor aiming to deliver a safe treatment for lupus sufferers read more innovative drug development for the benefit of patients worldwide read more aim listed headquarters in london and research centres in france and switzerland read more recent announcements update on corporate activities december 7, 2018 further analysis from its pivotal phase iii trial of lupuzor™ in patients with systemic lupus erythematosus (sle) shows positive results in the europe cohort 1 may 29, 2018 immupharma plc confident on lupuzor’s™ future april 23, 2018 successful placing to raise £10 million january 24, 2018 pharmaceutical drug development focused on making patient lives better immupharma plc is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. lupuzor ™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing lupus patients in its phase iii pivotal trial. this is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide. we continue to work with our long term partner centre national de la recherche scientifique (cnrs), europe’s largest fundamental research institution and immupharma’s long standing collaboration partner. aim listed developing innovative drugs immupharma plc is a pharmaceutical company listed since 2006 on aim of the london stock exchange (lse:imm), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. immupharma is focused on three therapeutic disease areas – auto-immune (p140) | oncology/ophthalmology | metabolism/diabetes. lupuzor ™ is the company’s most advanced drug candidate and is a treatment for lupus, a life threatening auto immune-disease. lupuzor ™ received ‘gold standard’ approval from the us fda for its phase iii trial with a special protocol assessment and “fast track” designation. the phase iii trial has now been completed. immupharma is led by a commercially focused board and management team with extensive experience. click here for the current corporate update in september 2018. rns announcements more share price loading... market cap 15 minute delayed share price provided by hemscott group limited disclaimer investor relations immupharma transforms care for people worldwide developing innovative drugs for serious medical conditions lead program for the potential breakthrough compound for lupus, the life threatening auto-immune disease immupharma has completed dosing lupus patients in the usa, europe and mauritius in a pivotal phase iii clinical trial of lupuzor ™ with top line results announced. more auto-immune diseases lupuzor ™, is also known by its chemical name ‘ forigerimod’ or p140. immupharma has the potential of expanding the p140 peptide platform into other auto immune conditions such as: rheumatoid arthritis, crohn’s disease, and asthma. very few aim-listed drug development companies have late-stage clinical assets of similar calibre. more oncology & ophthalmology immupharma’s second most advanced pipeline program, ipp-204106 , is a potential treatment for various cancers and acts by modulating angiogenesis (formation of new blood vessels) and proliferation (rapid reproduction). we are also investigating its use in age-related macular degeneration, diabetic retinopathy and other ophthalmological indications. more metabolism and diabetes immupharma’s subsidiary ‘ureka’ has initiated the development of a novel and innovative peptide technology platform through the collaboration with cnrs, gaining access to pioneering research centred on novel peptide drugs at the university of bordeaux and the institut européen de chimie et biologie (iecb). the first therapeutic area being targeted is diabetes. more we are focused on advancing the care of patients suffering from serious medical conditions worldwide. immupharma is aim listed with our headquarters in london and research centres in france and switzerland. to contact us click here aim rule 26 contact information disclaimer privacy policy site map © immupharma plc 2005-2017 | all rights reserved cookies this website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. if you want to know more or withdraw your consent to all or some of the cookies, please refer to the cookie policy i accept

URL analysis for immupharma.co.uk

https://www.immupharma.co.uk/contact-us/
https://www.immupharma.co.uk/products/auto-immune-diseases/
https://www.immupharma.co.uk/investors/email-alerts/
https://www.immupharma.co.uk/about-us/#research
https://www.immupharma.co.uk/media/scientific-publications/
https://www.immupharma.co.uk/news/
https://www.immupharma.co.uk/our-team/#team-fourth-row
https://www.immupharma.co.uk/cookie-policy/
https://www.immupharma.co.uk/our-team/board-of-directors/
https://www.immupharma.co.uk/investors/
https://www.immupharma.co.uk/folio/metabolism-and-diabetes/
https://www.immupharma.co.uk/broker-research/
https://www.immupharma.co.uk/media/events/
https://www.immupharma.co.uk/investors/market-commentary/
https://www.immupharma.co.uk/investors/corporate-governance/

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain name:
immupharma.co.uk

Registrant:
ImmuPharma plc

Registrant type:
UK Public Limited Company, (Company number: 3929567)

Registrant's address:
Broadway 50
London
SW1H 0RG
United Kingdom

Data validation:
Nominet was able to match the registrant's name and address against a 3rd party data source on 15-Aug-2017

Registrar:
1 & 1 Internet SE [Tag = 1AND1]
URL: https://www.1and1.co.uk

Relevant dates:
Registered on: 18-Dec-2004
Expiry date: 18-Dec-2019
Last updated: 15-Aug-2017

Registration status:
Registered until expiry date.

Name servers:
ns1025.ui-dns.org
ns1060.ui-dns.de
ns1106.ui-dns.biz
ns1111.ui-dns.com

WHOIS lookup made at 15:08:15 22-Mar-2018

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2018.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER co.uk.whois-servers.net

  ARGS immupharma.co.uk

  PORT 43

  TYPE domain

OWNER

  ORGANIZATION ImmuPharma plc

TYPE
UK Public Limited Company, (Company number: 3929567)

ADDRESS
Broadway 50
London
SW1H 0RG
United Kingdom
Data validation:
Nominet was able to match the registrant's name and address against a 3rd party data source on 15-Aug-2017

DOMAIN

  SPONSOR 1 & 1 Internet SE [Tag = 1AND1]

  CREATED 2004-12-18

  CHANGED 2017-08-15

STATUS
Registered until expiry date.

NSERVER

  NS1025.UI-DNS.ORG 217.160.83.25

  NS1060.UI-DNS.DE 217.160.80.60

  NS1106.UI-DNS.BIZ 217.160.81.106

  NS1111.UI-DNS.COM 217.160.82.111

  NAME immupharma.co.uk

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2018.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .